SNGXConference•prnewswire•
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sentiment:Neutral (45)
Summary
(NASDAQ:SNGX) PRINCETON, N.J., Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by prnewswire